What Stempoint Capital LP reported holding on Form 13F for the quarter ended Sep 30, 2026.
CIK 1952142 · Filed Nov 16, 2026
Values are as the managers reported them, in dollars.Open the Form 13F on SEC EDGAR
| 2.3M |
| +44.4% |
| $33.1M |
| 5.9% |
ABVXAbivax S.A. | 279.4K | −1.5% | $27.7M | 4.9% |
TNGXTango Therapeutics, Inc. | 989.3K | −19.1% | $24.7M | 4.4% |
ROIVRoivant Sciences Ltd. | 641.5K | +84.1% | $23.5M | 4.2% |
TRAXFirst Tracks Biotherapeutics, Inc. | 649.9K | +4.4% | $23M | 4.1% |
ELVNEnliven Therapeutics, Inc. | 330.5K | −4.7% | $15.1M | 2.7% |
ALKSAlkermes plc. | 333.3K | +34.4% | $13.5M | 2.4% |
ADPTAdaptive Biotechnologies Corp | 463.6K | New | $13.4M | 2.4% |
DNTHDianthus Therapeutics, Inc. | 150.8K | −24.9% | $13.3M | 2.4% |
FTHFaeth Therapeutics, Inc. | 404.9K | New | $12M | 2.2% |
SYRESpyre Therapeutics, Inc. | 132.2K | +23.7% | $11.8M | 2.1% |
IMTXImmatics N.V. | 1.3M | New | $11.5M | 2.1% |
GRALGrail, Inc. | 81.9K | New | $11.5M | 2.1% |
PRAXPraxis Precision Medicines, Inc. | 38.7K | +4.0% | $11.3M | 2% |
SRZNSurrozen, Inc. | 418.5K | −30.6% | $11.1M | 2% |
CCCCC4 Therapeutics, Inc. | 3.3M | +528.9% | $11M | 2% |
ACRSAclaris Therapeutics, Inc. | 2.1M | New | $10.8M | 1.9% |
DMRADamora Therapeutics, Inc. | 506.1K | New | $10.8M | 1.9% |
RVMDRevolution Medicines, Inc. | 50K | −68.7% | $10.3M | 1.8% |
CYTKCytokinetics Inc | 145.8K | +92.8% | $9.6M | 1.7% |
ONCBeOne Medicines Ltd. | 25.1K | New | $9.2M | 1.6% |
XENEXenon Pharmaceuticals Inc. | 222.3K | +192.2% | $8.3M | 1.5% |
JNJJohnson & Johnson | 30K | New | $7.9M | 1.4% |
TRVITrevi Therapeutics, Inc. | 552.2K | New | $7.9M | 1.4% |
LLYEli Lilly & Co | 6.6K | New | $7.6M | 1.4% |
ARWRArrowhead Pharmaceuticals, Inc. | 109.9K | +180.4% | $7.2M | 1.3% |
CERSCerus Corp | 3M | New | $7.1M | 1.3% |
IMVTImmunovant, Inc. | 201.3K | −27.2% | $6.8M | 1.2% |
JBIOJade Biosciences, Inc. | 471.7K | New | $6.6M | 1.2% |
GHGuardant Health, Inc. | 33.5K | New | $6M | 1.1% |
OABIOmniAb, Inc. | 1.2M | New | $6M | 1.1% |
COGTCogent Biosciences, Inc. | 184.2K | New | $5.9M | 1.1% |
BHVNBiohaven Ltd. | 396.9K | −62.7% | $5.3M | 0.9% |
MLYSMineralys Therapeutics, Inc. | 200K | −66.8% | $5M | 0.9% |
IDYAIDEAYA Biosciences, Inc. | 123.8K | New | $4.8M | 0.8% |
CELCCelcuity Inc. | 57.9K | −41.1% | $4.6M | 0.8% |
GHRSGH Research PLC | 195.1K | New | $4.6M | 0.8% |
EWTXEdgewise Therapeutics, Inc. | 111.6K | New | $4.5M | 0.8% |
IFRXInflaRx N.V. | 2.5M | −23.0% | $4.5M | 0.8% |
IPSCCentury Therapeutics, Inc. | 2.6M | +19.5% | $4.4M | 0.8% |
BDSXBiodesix Inc | 141.5K | +102.2% | $4.2M | 0.8% |
BNTXBioNTech SE | 42.2K | New | $4.1M | 0.7% |
SNYSanofi | 99.9K | New | $4.1M | 0.7% |
AURAAura Biosciences, Inc. | 647.4K | −9.4% | $4.1M | 0.7% |
CGONCG Oncology, Inc. | 54.8K | −65.6% | $3.9M | 0.7% |
NAMSNewAmsterdam Pharma Co N.V. | 159K | +105.0% | $3.9M | 0.7% |
KNSAKiniksa Pharmaceuticals International, plc | 51.8K | −75.2% | $3.9M | 0.7% |
VRDNViridian Therapeutics, Inc.DE | 187.3K | New | $3.9M | 0.7% |
VORVor Biopharma Inc. | 200.8K | New | $3.8M | 0.7% |
LBRXLB Pharmaceuticals Inc | 91.8K | +188.7% | $3.5M | 0.6% |
EDSAEdesa Biotech, Inc. | 825K | New | $3.5M | 0.6% |
AVLNAvalyn Pharma Inc. | 118K | ±0% | $3.4M | 0.6% |
ISRGIntuitive Surgical Inc | 8.1K | New | $3.3M | 0.6% |
NRIXNurix Therapeutics, Inc. | 138K | New | $3.3M | 0.6% |
OVIDOvid Therapeutics Inc. | 1.3M | −46.7% | $3.2M | 0.6% |
CUECue Biopharma, Inc. | 108.6K | +62.2% | $2.8M | 0.5% |
UTHRUnited Therapeutics Corp | 4.6K | New | $2.5M | 0.4% |
DYNDyne Therapeutics, Inc. | 154.2K | New | $2.5M | 0.4% |
ATTOAttovia Therapeutics, Inc. | 138.2K | New | $2.4M | 0.4% |
ORKAOruka Therapeutics, Inc. | 27.3K | −76.6% | $2.3M | 0.4% |
INSMInsmed Inc | 19.6K | New | $2.2M | 0.4% |
WGSGeneDx Holdings Corp. | 29.3K | New | $2.1M | 0.4% |
PHVSPharvaris N.V. | 66.3K | −18.0% | $2.1M | 0.4% |
WHWKWhitehawk Therapeutics, Inc. | 496K | −51.4% | $1.9M | 0.3% |
MNPRMonopar Therapeutics | 23.3K | −22.6% | $1.9M | 0.3% |
HLXCHelix Acquisition Corp. III | 171.7K | ±0% | $1.8M | 0.3% |
ARQTArcutis Biotherapeutics, Inc. | 61.2K | −38.2% | $1.6M | 0.3% |
AEMDAethlon Medical Inc | 213.7K | New | $1.4M | 0.2% |
TCGXTCGX Acquisition Corp. | 100K | New | $1.3M | 0.2% |
SABSSAB Biotherapeutics, Inc. | 352.7K | +2.9% | $1.1M | 0.2% |
JTTTJATT III Acquisition Corp | 100K | New | $1.1M | 0.2% |
QNRXQuoin Pharmaceuticals Ltd. | 236.2K | New | $1.1M | 0.2% |
ADRXADARx Pharmaceuticals, Inc. | 52K | New | $1M | 0.2% |
STLNStarling Oncology, Inc. | 156.7K | New | $990.1K | 0.2% |
CLRBCellectar Biosciences, Inc. | 447.4K | +26.0% | $823.1K | 0.1% |
ANROAlto Neuroscience, Inc. | 21.8K | New | $555.6K | 0.1% |
CALCCalciMedica, Inc. | 249K | New | $403.3K | 0.1% |
| 60K | New | $255.3K | 0.1% |
| 75K | New | $226.1K | 0.1% |
BRVEBraveheart Bio, Inc. | 10K | New | $202K | 0.1% |
RLMDRelmada Therapeutics, Inc. | 44.1K | −97.0% | $166.4K | 0.1% |
| 25K | New | $143.8K | 0.1% |
| 10K | New | $106.5K | 0.1% |
ARK ETF TRGENOMIC REV ETFPut option | 450K | +350.0% | $102.5K | 0.1% |
| 75K | New | $88.1K | 0.1% |
SPDR SERIES TRUSTST STR SP BIOTPut option | 375K | +50.0% | $71.3K | 0.1% |
| 30K | New | $55.5K | 0.1% |
| 15K | New | $52.5K | 0.1% |
VTGNVistagen Therapeutics, Inc. | 337.9K | −45.2% | $24.7K | 0.1% |
| 45K | New | $15.8K | 0.1% |